Patients with diabetes who have undergone early-generation drug-eluting stent (DES) placement have nearly triple the risk of all-cause and cardiac death compared with patients without diabetes, say researchers from Bern University Hospital, Triemli Spital, and University of Bern, all in Switzerland. However, their study also found that diabetes did not increase the risk of myocardial infarction (MI) and stent thrombosis, repeat revascularization, or delayed lumen loss.
More Headlines